Sensorion's SENS-401 fails to meet primary goal in Phase II SSNHL trial

Sensorion announced that Phase II trial of SENS-401 (Arazasetron) to treat sudden sensorineural hearing loss failed to meet primary goal.

Related Keywords

France , ,Ethics Committee Of Strasbourg ,Monitoring Solutions For Clinical ,Clinical Trials Arena ,Independent Ethics Committee ,Real Time Tracking ,Monitoring Solutions ,Cellular Immune ,